\n\u201cNe-am dep\u0103\u015fit \u0163intele financiare propuse datorit\u0103 cererii sus\u0163inute pentru produsele noastre \u015fi lans\u0103rii de noi medicamente \u015fi teste de diagnostic\u201d, a declarat Severin Schwan, CEO al Roche.<\/p>\n
\nV\u00e2nz\u0103rile Diviziei de Farmaceutice a Roche au crescut cu 7% \u00een anul 2013, ajung\u00e2nd la 36,3 miliarde de franci elve\u0163ieni. Aceast\u0103 cre\u015ftere s-a datorat \u00een special produselor din portofoliul de oncologie, dar \u015fi perfoman\u0163elor \u00eenregistrate de medicamentele destinate tratamentului poliartritei reumatoide. V\u00e2nz\u0103rile au \u00eenregistrat o cre\u015ftere de 10% \u00een Statele Unite, de 12% pe pie\u0163ele emergente, \u015fi de 2% \u00een Europa \u015fi Japonia.<\/p>\n
\n\u00cen anul 2013, linia de cercetare \u015fi dezvoltare a Diviziei de Farmaceutice a Grupului Roche a \u00eenregistrat progrese deosebite mai ales \u00een domeniul oncologiei, oftalmologiei \u015fi bolilor autoimune. Linia de cercetare \u015fi dezvoltare a Roche include 66 de noi entit\u0103\u0163i moleculare, dintre care 15 sunt \u00een ultimele faze de dezvoltare.<\/p>\n
\n\u00cen anul 2013, v\u00e2nz\u0103rile Diviziei de Diagnostic au crescut cu 4%, ridic\u00e2ndu-se la 10,5 miliarde de franci elve\u0163ieni, \u00een principal datorit\u0103 cererii sus\u0163inute pentru testele \u015fi echipamentele folosite \u00een laboratoarele clinice, oferite de Roche Professional Diagnostics (+8%).<\/p>\n
\nPentru anul 2014, Roche prognozeaz\u0103 o cre\u015ftere a v\u00e2nz\u0103rilor de aproximativ 5%, la o rat\u0103 de schimb constant\u0103 \u015fi o cre\u015ftere a dividendelor.<\/p>\n","protected":false},"excerpt":{"rendered":"
Grupul farmaceutic elve\u0163ian Roche anun\u0163\u0103 o cre\u015ftere a v\u00e2nz\u0103rilor globale \u00een anul 2013, cu 6%, la o rat\u0103 de schimb constant\u0103, ajung\u00e2nd la 46.8 miliarde franci elve\u0163ieni, datorit\u0103 cererii crescute pentru medicamentele destinate tratamentului cancerului, bolilor autoimune \u015fi pentru testele de diagnostic destinate laboratoarelor clinice.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[323,8623,7212],"class_list":["post-103736","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-medicamente","tag-roche","tag-vanzari"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/103736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=103736"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/103736\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=103736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=103736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=103736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}